Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
| 08-2020 | 08-2019 | 08-2018 | 08-2017 | 08-2016 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 113 | 61 | 2 | 1 | 1 |
| Accounts receivable | -91 | -139 | -245 | -8 | -6 |
| Accounts payable and accrued liabilities | -49 | 101 | 3 | -40 | 57 |
| Other Working Capital | -161 | 80 | -371 | -301 | 338 |
| Other Operating Activity | -2,475 | -3,108 | -1,907 | -1,198 | -1,050 |
| Operating Cash Flow | $-2,663 | $-3,006 | $-2,518 | $-1,546 | $-661 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -646 | 0 | 0 | -3 |
| Net Acquisitions | N/A | 0 | -70 | N/A | N/A |
| Sale Of Investment | 7 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -34 | -123 | -85 | -10 | -17 |
| Investing Cash Flow | $-27 | $-769 | $-155 | $-10 | $-20 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 31 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 2,668 | 2,333 | 1,867 | 4,046 | 419 |
| Other Financing Activity | 0 | 1,000 | 0 | -50 | 95 |
| Financing Cash Flow | $2,699 | $3,333 | $1,867 | $3,996 | $514 |
| Beginning Cash Position | 1,285 | 1,727 | 2,533 | 93 | 260 |
| End Cash Position | 1,294 | 1,285 | 1,727 | 2,533 | 93 |
| Net Cash Flow | $9 | $-442 | $-806 | $2,440 | $-167 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,663 | -3,006 | -2,518 | -1,546 | -661 |
| Capital Expenditure | -34 | -769 | -85 | -10 | -20 |
| Free Cash Flow | -2,697 | -3,775 | -2,603 | -1,556 | -681 |